CV labs Flashcards

1
Q

CPK

A

transfers high energy phosphate between creatine and ADP. Fraction MM from muscle and BB from brain, yet myocardial infarct = increased MB fraction, ie. CPK-MB.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Troponin

A

Calcium causes a conformational change in tropomysin that allows the reaction between actin and myosin to proceed. A free fraction in cytoplasm allows early leakage during an MI, resulting in a rise with the CPK. The troponin stays elevated for 5-10 days whereas the CPK usually hits normal at 3 days. Higher sensitivity test for troponin are now available.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Reinfarction after 3 days could be diagnosed with

A

a CK-MB elevation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

different types of troponin

A

Troponin consists of three single chain polypeptides which regulate muscle contraction: troponin C (binds Ca2+), troponin I (binds actin-inhibiting actin–myosin interaction), and troponin T (binds tropomyosin and facilitates contraction). Cardiac muscle contains specific cTnI and cTnT isoforms. Most cTn is bound, but a small amount is free in the cytosol. The initial rise of cTn after myocyte damage is thought to be release of the unbound cytosolic cTn. This is followed by more prolonged appearance of troponin from damage to the myofilament structures.*

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what causes changes in troponin?

A

AMI = elevated or falling troponin I or T* on the basis of ischemia in the presence of appropriate clinical information, EKG changes or new wall motion abnormality.

Elevation may be due to an acute injury (ie, pericarditis, myocardititis, pulmonary embolism, sepsis), or a chronic process (ie LVH, CHF, CKD, or DM); rather than an infarction which is based on ischemia.

Troponins can be used to diagnose cardiac injury after PCI (5 fold increase) or CABG (must have 10 fold increase).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The diagnosis of an acute myocardial infarction depends on

A

observation of a rise and/or fall of blood biomarkers with at least one value above the 99th percentile. Cardiac troponins are preferred to CK-MB measurements for diagnostic and prognostic purposes. A change in troponin levels is needed to diagnose myocardial infarction because troponin elevation can also be seen in a variety of other diseases, such as sepsis, hypovolemia, atrial fibrillation, heart failure, pulmonary embolism, myocarditis, myocardial contusion, and renal failure.
**Thus, an increased or falling troponin must be accompanied with symptomatic, electrocardiographic, nuclear, or echocardiographic evidence of myocardial ischemia in order to diagnose a myocardial infarction!. **

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

A 45 y/o male presents with substernal chest pain of three hours duration. A highly sensitive troponin I assay is elevated. EKG is as shown. What should be done next?

A

Repeat the troponin in 2 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

MI/hs-cTnT When are they sensitive enough to detect an MI?

A

High sensitivity troponins* (hs-cTnT) are now able to confirm MI in 2 hours.

Some patients who present 2 hours or more after onset of chest pain, with a TIMI of 0 or 1, and with a negative one hour hs-cTNT (no changes in an hour) can be sent home.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what does cTnT of more than 14 ng/L indicate?

A

In patients with stable ischemic heart disease, a highly sensitive troponin (cTnT) of > 14 ng/L indicates an increased risk of MI, stroke, CHF, or CV death.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

hsCRP

A

Released by hepatocytes under influence of cytokines IL6 and TNF alpha.

May bind to oxidized LDL particles for macrophage ingestion.

Useful in “stable” CHD in that a level > 3 mg/L = worse prognosis.

Useful in ACS where a level > 10 mg/L = worse prognosis.

hsCRP is decreased by statins and thiozolinediones.

Best level of hsCRP is

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Lipids lab testing

A

Total cholesterol, triglycerides and HDL-C (done fasting due to triglycerides).

LDL-C = total-C – [VLDL-C (1/5 trig) + HDL-C]. This only works for triglycerides

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Non-HDL-C

A

= total C – HDL-C = cholesterol in LDL, lipoprotein (a), IDL and VLDL. Better measurement of risk than LDL-C

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

LDL-C

A

level does not reveal the number of LDL particles, ie one may have a relatively normal LDL-C with level of 100 mg/dL and yet have many more small dense and dangerous particles than someone else with an LDL-C level of 100*.

*LDL-P (a core of lipid surrounded by phospholipid) measured by NMR
spectroscopy is a better assessment of lipid status than LDL-C or
Apo-B.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Which of the following lab test is best for supporting the
diagnosis of cardiovascular disease?

hs CRP
Myeloperoxidase 
Homocysteine
Cholesterol 
Fibrinogen
A

Cholesterol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

BNP*

A

Brain naturetic peptide – mainly from cardiac ventricles (ANP mainly from atria) and activates G-protein coupled receptors.
BNP inhibits RAAS, endothelin secretion and sympathetic activity (norepinephrine), and increases renal blood flow and sodium excretion.
Useful in accessing severity in ACS, stable angina, mitral regurgitation, and aortic stenosis, but not to be used to guide treatment.

***Aberrantly low in obesity.

Uses:
Evaluation of dyspnea: 100 – 400 pg/mL = No value. Greater than 400 pg/mL = possible CHF. Less than 100 pg/mL = no CHF.***
Monitoring of established HF (fair) and prognosis in CHF (better).
May be of use in heart failure therapy, ie nesiritide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

N-terminal Pro-BNP*

A

NT proBNP useful to suggest CHF in in patients with dyspnea less than 50 , 50-75 and > 75 yoa at levels of 450pg/mL, 900 pg/mL and 1800 pg/mL respectively.

Age > 70, NT proBNP less than 400 pg/ml excludes CHF, and NT proBNP > 2000 pg/ml suggest CHF when diagnosis is uncertain.

17
Q

Acute heart failure can be ruled out with normal levels of

A

BNP and NTproBNP

18
Q

Serum Sodium

A

A marker for a poor prognosis in CHF.

Na below 135 meq/L indicates that a CHF patient has an increased chance of falls as well as more likely reoccurrence of CHF episodes.

Related to excess vasopressin (ADH)

19
Q

Which of the following would be the best marker for the severity of CHF?

Serum sodium
BNP 
NT Pro-BNP
Uric acid
Fibrinogen
A

Serum sodium

20
Q

Which of the following cardiac markers is useful in excluding congestive heart failure?

hsCRP
myeloperoxidase 
homocysteine
Cholesterol
NT-pro BNP
A

NT-pro BNP

21
Q

Other Lab Methods of Risk Assessment

A
TC/HDL-C
Non-HDL-C
Apolipoprotein B
Apolipoprotein (a)
Small dense LDL-C
LDL-P
22
Q

High Cholesterol with High LDL-C

A

High cholesterol with high LDL-C (Fredrickson type 2A) is a lab presentation that includes Familial and Polygenic Hypercholesterolemia*.

All relate to high LDL-C (with essentially normal triglycerides) because of a **defective LDL receptor or problems with LDL-C attachment **(defective apo B ligand) to the receptor or various combinations thereof.

Patients have corneal arcus, xanthelasma and tendinous xanthomata, premature CAD, and aortic stenosis.

23
Q

Type IIa Hyperlipidemia

A

Familial or Polygenic Hyperlipidemia

Mutation in LDL receptors or defective Apo B 100 ligand (90% Type II a ). LDL - C usually > 250 mg/dl. Tendon xanthomas, arcus, premature CAD, PVD, strong family history.

24
Q

High Cholesterol with High Triglycerides

A

High Cholesterol with High Triglycerides = Fredrickson Types 2B or Familial Combined Hyperlipidemia (most common primary hyperlipidemia, though usually no skin findings).

25
Q

Type II B Hyperlipidemia

A

Familial Combined Hyperlipidemia

Increased hepatic secretion of VLDL with Apo B 100 and conversion to LDL with Apo B 100 [10% of type II a (increased LDL); IIb (inc. LDL and inc. VLDL); Type IV]. Common, often hypertensive and obese, no xanthomas, early CAD, PVD, stroke. Acquired type in diabetics. Most common cause of lactescent plasma and primary hyperlipidemia.

26
Q

A 50 y/o obese diabetic female presents with BP of 160/86. Pedal pulses are diminished. Past history is positive for a TIA. There are no xanthomas. Serum is lactescent with LDL cholesterol of 210 mg/dL and triglycerides of 340 mg/dL. This patient most likely has:

A

familial combined hyperlipidemia.

27
Q

High Cholesterol with equally High Triglycerides

A

High Cholesterol with High Triglycerides = Type 3 (dysbetalipoproteinemia or “broad beta disease” with an abnormal IDL). This combination is seen in:

**Dysbetalipoproteinemia (E2/E2 – equal elevation of cholesterol and triglycerides).

**Hepatic lipase deficiency which can present like “Broad Beta disease” also plays a role in ineffective clearance of IDL.

28
Q

A 45 y/o male with a history of gout and the metabolic syndrome presents with intermittent claudication and a strange rash on the hands and elbows. Lipid profile shows a cholesterol of 680 mg/dL with triglyceride of 700 mg/dL. Serum is turbid with standing.
This patient has which hyperlipoproteinemia?

A

III

29
Q

When do I have my cholesterol tested?”

A

USPFTS
Lipid screening should start at age 35 in men without other risk factors for coronary artery disease and at age 20 to 35 in men with risk factors (FH, smoking, HTN).

Lipid screening should start at age 45 in women, and maybe at age 20 in those with risk.

30
Q

CHD equivalents

A

DM, TIA, PAD, AAA, 10-year risk of CHD > 20%

31
Q

Risk Stratification (ATP III)

A

Fasting lipid profile

Identify CHD equivalents (DM, TIA, PAD, AAA, 10-year risk of CHD > 20%). If present, the cholesterol goal is LDL-C

32
Q

ACC, AHA, and NHLB Cholesterol Guidelines

A

Clinical atherosclerotic cardiovascular disease:
High intensity treatment/atorvastatin 40-80 mg or rosuvastatin 20 – 40
mg.

Primary elevations of LDL-C > 190 mg/dL:
High intensity treatment/atorvastatin 40-80 mg or rosuvastatin 20 - 40 mg.

Diabetic patients without clinical ASCVD aged 40-75 years with LDL-C 70-189 mg/dL, but with 10-year atherosclerotic CVD > 7.5%: High intensity treatment/atorvastatin 40-80 mg or rosuvastatin 20 - 40 mg.

Diabetic patients without clinical ASCVD aged 40-75 years with LDL-C 70-189 mg/dL, and 10-year ASCVD less than 7.5%: Moderate intensity treatment/atorvastatin 10-20 mg or rosuvastatin 5-10 mg.

Primary prevention patients with LDL-C 70-189 mg/dL and estimated 10-
year atherosclerotic CV risk > 7.5 %:

Primary prevention patients with LDL-C 70-189 mg/dL and estimated 10-
year atherosclerotic CV risk less than 7.5 %: Observe*

33
Q

2013 ACC/AHA Assessment of CV Risk

A

10 year risk based on: Sex; Age; **Race; HDL-C; TC; BP(untreated or treated); Smoker; Diabetes.

  • Statin therapy for :
    1. Individuals with clinical ASCVD.

    2. Individuals with primary elevations of LDL ≥ 190 mg/dL.***
    3. Individuals 40 to 75 **years of age with diabetes and an LDL 70 to 189 mg/dL without clinical ASCVD.
    4. Individuals without clinical ASCVD or diabetes who are 40 to 75 years of age with LDL 70 to 189 mg/dL and a 10-year ASCVD risk of 7.5%
    or higher.
34
Q

10 year risk evaluation for ages 40-79

A
*Gender
Age
*Race –AA or whites and others
TC
HDL-chol
SBP
*Treatment for HBP
Diabetes
Smoker
35
Q

PCSK9

A

The first genetically based therapy for lipids, approved by the FDA late 2015

PCSK9 appears to be twice as effective as statins in reducing CV outcomes
Statins reduce outcomes by 35%, PCSK9 by 85%
Only available by injection q 2 weeks. Two drugs approved late in 2015. Insurance companies starting to approve these drugs